BioSpace
By BioSpace
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by BioSpace
Category: Life Sciences
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 8
Reviews: 0
Episodes: 227
Description
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
| Episode | Date |
|---|---|
|
Pfizer, Lilly, more report Q1, FDA names acting CBER director and an ALS awakening
|
May 06, 2026 |
|
What makes life science angel investment work?
|
Apr 30, 2026 |
|
Q1 earnings take off, Lilly strikes deals, Regeneron notches historic approval, FDA raises questions
|
Apr 29, 2026 |
|
The next era of diabetes management
|
Apr 23, 2026 |
|
Trump’s psychedelics push, Lilly’s up to $7B CAR T deal, Replimune’s saga and Denali’s big win
|
Apr 22, 2026 |
|
Funding the Future of European Biotech
|
Apr 16, 2026 |
|
J&J targets $100B revenue, Replimune rebuffed again and a “Revolution” in pancreatic cancer
|
Apr 15, 2026 |
|
Bonus: Q1 2026 Job Market Update
|
Apr 14, 2026 |
|
Automation, Collaboration and the Future of Advanced Therapies
|
Apr 09, 2026 |
|
Lilly’s Foundayo Nod Launches New Battle With Novo, M&A Mania Continues, Tariffs Hit Pharma
|
Apr 08, 2026 |
|
The Radiotherapeutics Moment: How Isotopes are Changing Cancer Treatment
|
Apr 02, 2026 |
|
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes
|
Apr 01, 2026 |
|
Beyond Buzzwords in Longevity Investing
|
Mar 26, 2026 |
|
Gilead’s Ouro Buy, J&J/Protagonist’s Approval, Aurinia’s Revamp, ACIP Confusion, More
|
Mar 25, 2026 |
|
Inside the Race to Build the Next Generation of AI Drug Discovery Platforms
|
Mar 19, 2026 |
|
Kennedy’s Vaccine Agenda Stalled, Structure’s ‘Competitive’ Obesity Pill, Novo’s Warning Letter
|
Mar 18, 2026 |
|
From Two Trials to One, Sponsors Face a Higher Standard
|
Mar 12, 2026 |
|
Prasad Out at FDA, Lawmaker Takes Action on Rare Disease Rejections and a Spate of Obesity Data
|
Mar 11, 2026 |
|
Rising Amid Flurry of CAR T Deals, Stylus Proves Cell Therapy Is Not Dead
|
Mar 10, 2026 |
|
From Grants to Family Offices: Building a Unified Financing Strategy in Biotech
|
Mar 05, 2026 |
|
UniQure’s Delay, REGENXBIO’s Rejection Explained, Sarepta’s Ingram Steps Down, More
|
Mar 04, 2026 |
|
ALS Advances Unite Patients and Pharma on Novel Targets, Biomarker Breakthroughs
|
Feb 26, 2026 |
|
Lilly Bests Novo Again, Rare Disease Week Goes Regulatory, More CDC Leadership Upheaval
|
Feb 25, 2026 |
|
Corsera Eyes Two-Pronged Approach To Tackle Leading Cardiovascular Killer
|
Feb 24, 2026 |
|
Redefining Obesity Treatment Beyond GLP-1 Limits
|
Feb 19, 2026 |
|
Modernagate Fallout, Disc’s Rejection, Compass’ Psilocybin Data, CDC’s Lost Leaders
|
Feb 18, 2026 |
|
As FDA Moves Away From Animal Testing, AI and Organoids Can Shine
|
Feb 17, 2026 |
|
Digital Pathology, AI and the Future of ADCs and HER2 Cancer Treatment
|
Feb 12, 2026 |
|
Weight Loss Drama Compounds on Heels of Novo, Lilly Earnings, Plus Gene Therapy News
|
Feb 11, 2026 |
|
Programmable RNA 2.0: Beyond the First mRNA Revolution
|
Feb 05, 2026 |
|
Pfizer’s Metsera Data, 2025 Earnings, the FDA and REGENXBIO, Psychedelics and IPOs
|
Feb 04, 2026 |
|
Biotech’s New Cycle, JPM Deal Hype and Where Alpha Still Hides
|
Jan 29, 2026 |
|
Roche Makes Obesity Splash, Moderna Cans Vaccine Trials, Sarepta’s New Data, More
|
Jan 28, 2026 |
|
From Sound Bites to Signals: Editors Parse Executive and Investor Chatter at JPM
|
Jan 22, 2026 |
|
JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return
|
Jan 21, 2026 |
|
Bonus: Q4 2025 Job Market Update
|
Jan 19, 2026 |
|
Deals Roll at JPM26, Policy Front and Center, IPOs Are Back, FDA Stays Busy
|
Jan 14, 2026 |
|
From Nuclear Winter to Renewal: Biotech Investing for 2026
|
Jan 08, 2026 |
|
Novo Launches Oral Obesity Pill, Lilly Targets Lofty Revenue, FDA and M&A in Focus
|
Jan 07, 2026 |
|
Inside the 2026 Biotech Landscape: Innovation, Investment and Global Momentum
|
Dec 18, 2025 |
|
Lilly’s Triple Triumph, Prasad’s COVID Error, J&J’s Surprise Voucher, M&A Targets
|
Dec 17, 2025 |
|
Beyond the Gluten-Free Diet: A New Era in Celiac Disease Treatment
|
Dec 11, 2025 |
|
Weight Loss Waves, Pazdur’s Exit and FDA Instability, New Neuro Breakthroughs
|
Dec 10, 2025 |
|
New Approach Methodologies: Redefining Animal Testing Alternatives
|
Dec 04, 2025 |
|
Prasad’s Leaked FDA Memo, Alzheimer’s Ups and Downs, Next-Gen Obesity Drugs
|
Dec 03, 2025 |
|
Billions More in M&A, Another Bidding War and More FDA Drama
|
Nov 19, 2025 |
|
How Biotech Funding is Changing Executive Search and Hiring Processes
|
Nov 13, 2025 |
|
Pfizer Wins Metsera, Trump Strikes GLP-1 Pricing Deal, FDA Awards More Priority Vouchers
|
Nov 12, 2025 |
|
Thoughtful Tech: How Removing Technological Burdens Can Improve Clinical Trial Compliance and Patient Experience
|
Nov 06, 2025 |
|
Pfizer and Novo Battle Over Metsera, Tidmarsh Fights FDA Exit, UniQure and Sarepta Face Setbacks
|
Nov 05, 2025 |
|
Innovation, Resilience, and the Future of Global Manufacturing
|
Oct 30, 2025 |
|
Novartis’ Big Buy, Q3 Earnings, Regeneron’s Dropped Cell Therapy, More
|
Oct 29, 2025 |
|
How Supply Chain Turbulence is Reshaping Biotech Strategy
|
Oct 23, 2025 |
|
Novo Board Upended, ESMO Excitement, FDA Awards, Replimune’s U-Turn
|
Oct 22, 2025 |
|
Cost Control to Capability Building: Rethinking Supply and Strategy in Pharma
|
Oct 21, 2025 |
|
Work Smart, Build Trust: Connecting Technology, Patient Compliance and Data Processing
|
Oct 16, 2025 |
|
Q3 Earnings Are Here, Novo Ditches Cell Therapy but Buys Akero, Gov’t Shutdown Hits CDC
|
Oct 15, 2025 |
|
Bonus: Q3 2025 Job Market Update
|
Oct 14, 2025 |
|
Shutdown Pauses New Drug Reviews, CDC Issues New COVID Guidance, CGT Meets on Mesa
|
Oct 08, 2025 |
|
Hit Me With Your Best Shot: Understanding Autoinjectors and Combination Drug Delivery Systems
|
Oct 02, 2025 |
|
M&A Picks Up, Walmsley Moves On, Pfizer’s MFN Deal and Hope for Huntington’s
|
Oct 01, 2025 |
|
FDA’s Autism Endeavor, Pfizer’s Obesity Comeback Bid, Psychedelics Revival, ACIP Confusion, More
|
Sep 24, 2025 |
|
What Do AI and Hammers Have in Common?
|
Sep 18, 2025 |
|
China Crackdown, UK Exit, Novo Layoffs, Adcomm Flip Flop, More
|
Sep 17, 2025 |
|
Unpacking the Latest MAHA Report, RFK’s Senate Appearance, FDA’s CRL Drop and More
|
Sep 10, 2025 |
|
The 'Research Safety Net' Saving Scientists from Funding Crisis
|
Sep 04, 2025 |
|
CDC Faces Critical Meetings Amid COVID Vaccine Uncertainty, Plus Deals, FDA Approvals, More
|
Sep 03, 2025 |
|
Lilly’s Obesity Pill Heads to the FDA, AbbVie Bets on Psychedelics, HHS Unveils More Change
|
Aug 27, 2025 |
|
Oral Weight-Loss Race Heats Up as New Data From Lilly, Viking Reset Expectations
|
Aug 26, 2025 |
|
Why AI Won't Save the 90% of Clinical Trials That Still Fail
|
Aug 21, 2025 |
|
MAHA Report Emphasizes Vaccines, Safety Vexes Viking’s Obesity Win, Novo Gains Momentum
|
Aug 20, 2025 |
|
The Hidden Patent Crisis That Could Break Biotech: What Every CEO Needs to Know
|
Aug 14, 2025 |
|
Prasad Returns, Delany Departs, Lilly’s Weight Loss Pill Disappoints and Sarepta’s Fallout Continues
|
Aug 13, 2025 |
|
From Chat Bots to World Order: The Race for the 21st Century's Operating System
|
Aug 07, 2025 |
|
FDA In Flux, Pfizer Talks to Trump on MFN, Merck Cuts 6K Jobs, More
|
Aug 06, 2025 |
|
We Don't Own Patient Data–We're Just Babysitting It
|
Jul 31, 2025 |
|
Sarepta Gets Reprieve, RFK Jr.’s New Changes, Roche’s Alzheimer’s Comeback and Q2 Earnings
|
Jul 30, 2025 |
|
Sarepta’s Wild Week, CDER’s New Leader, FDA Rejections, Manufacturing Billions
|
Jul 23, 2025 |
|
Why Countries Are Racing to Build mRNA Factories While America Hesitates on Next-Gen Vaccines
|
Jul 22, 2025 |
|
AI Is Taking Over Drug Safety Monitoring–But There's One Thing It Can't Replace
|
Jul 17, 2025 |
|
FDA Layoffs, 200 Rejection Letters, User Fees and Priority Vouchers, Bad Week for Rare Disease
|
Jul 16, 2025 |
|
Bonus Episode: Q2 2025 Job Market Update
|
Jul 15, 2025 |
|
The mRNA Revolution You Haven't Heard About: From Cystic Fibrosis to Personalized Cancer Vaccines
|
Jul 10, 2025 |
|
Second Half Milestones, KalVista’s Surprise Approval, Another RFK Jr. Lawsuit, More
|
Jul 09, 2025 |
|
CAR T Expands, M&A Ticks Up, Two Psychedelics Read Out, and the Supreme Court Rules on PrEP
|
Jul 02, 2025 |
|
Understanding the FDA's AI Guidance in Pharmacovigilance
|
Jul 01, 2025 |
|
FDA Churn Continues, RFK Faces Congress, Obesity Insights at ADA, BIO2025 Recap
|
Jun 25, 2025 |
|
Navigating Funding Freezes and AI Frontiers
|
Jun 19, 2025 |
|
Another Gene Therapy Death; Biopharma M&A Picks Up; a Vaccine Board of Vaccine Skeptics
|
Jun 18, 2025 |
|
RFK Axes CDC Vaccine Advisors ; Metsera’s Weight Loss Win; FDA Supports CGT
|
Jun 11, 2025 |
|
AI's Role in Decoding the FDA's New Regulatory Communications
|
Jun 05, 2025 |
|
M&A Ticks Up, ASCO Excites and Vaccines Cause More Drama
|
Jun 04, 2025 |
|
COVID-19 Vaccine Overhaul, Rocket Grounded, ‘One Tough Hombre’ on MFN
|
May 28, 2025 |
|
How Target Product Profiles Guide the Industry Through Uncertain Times
|
May 22, 2025 |
|
Pfizer’s $6B China Deal, Drug Pricing and FDA’s New COVID Vaccine Plan
|
May 21, 2025 |
|
Trump’s Drug Pricing Policy, Prasad’s CBER Nod, Bayer’s Layoffs and Galapagos’ Next Chapter
|
May 14, 2025 |
|
Eroding Immunity: Vaccine Hesitancy and Cynicism
|
May 08, 2025 |
|
Trump’s US Manufacturing Push, New Vaccine Policy, Novo’s Weight Loss Pill up for FDA Review
|
May 07, 2025 |
|
Tariffs Continue to Dominate Q1 Earnings, AACR Excites Cancer Space, CEO Pay Gaps, More
|
Apr 30, 2025 |
|
Economic Challenges, Strategic Investments: Reshaping the Women's Health Landscape
|
Apr 24, 2025 |
|
Makary’s First Interview, US Manufacturing Push and Lilly vs. Novo in Obesity Pill Race
|
Apr 23, 2025 |
|
Tariff Turmoil, FDA’s Future, Pfizer’s Obesity Setback and CEO Salaries Revealed
|
Apr 16, 2025 |
|
Bonus: Q1 2025 Job Market Update
|
Apr 15, 2025 |
|
Breaking Down Barriers: The Nuanced Approach to Women's Representation in Medical Research
|
Apr 10, 2025 |
|
Tariff-Triggered Recession Fears, Fallout From HHS Cuts, Knockoff GLP-1s and More
|
Apr 09, 2025 |
|
FDA on Fire, Novo’s Mixed Bag of Semaglutide Cardio Data, Kisunla’s EU Miss, More
|
Apr 02, 2025 |
|
Balancing Protection and Inclusion: The Evolution of Women in Clinical Trials
|
Mar 27, 2025 |
|
Trump’s Pharma Tariffs, Monarez for CDC, Novo’s New Obesity Play, More
|
Mar 26, 2025 |
|
Sarepta’s Elevidys Death, FDA’s Vaccine Move, Weldon Whiplash, PDUFAs in Cardio
|
Mar 19, 2025 |
|
A Conversation With Mark McKenna, CEO of Mirador
|
Mar 18, 2025 |
|
“Perfect Patient” Industry Burdens; Exits and Investment in Women’s Health
|
Mar 13, 2025 |
|
COVID Reflections, Novo’s Next-Gen Weight Loss Struggles, Another Depression Miss, More
|
Mar 12, 2025 |
|
Tariff Threat Continues, More Meetings Cancelled, AbbVie Makes Obesity Play, More
|
Mar 05, 2025 |
|
A Conversation With Kevin Marks, CEO of Delphia
|
Mar 04, 2025 |
|
Money Meets Medicine: A Disruptor's Guide to Life Sciences Investment
|
Feb 27, 2025 |
|
Trump’s Pharma Tariffs, Another GLP-1 Compounding Lawsuit, Bluebird’s Bailout, More
|
Feb 26, 2025 |
|
Examining Gene Therapies, Bispecific Antibodies and Other Novel Modalities
|
Feb 25, 2025 |
|
Trump’s Hammer Hits FDA, Moderna Falls Further and Patent Cliffs Loom
|
Feb 19, 2025 |
|
A Conversation With Dannielle Appelhans, CEO of COUR
|
Feb 18, 2025 |
|
Navigating Patient Journeys with Tom Whitehead
|
Feb 13, 2025 |
|
New M&A Action, BMS’ Ongoing Cost Cuts and the Insatiable Demand for Weight Loss Drugs
|
Feb 12, 2025 |
|
RFK Jr. Advances, Q4 Earnings Roll Out and a Non-Opioid Pain Drug Hits the Market
|
Feb 05, 2025 |
|
The Patient's Perspective with Tom Whitehead
|
Jan 30, 2025 |
|
RFK Jr. Faces the Senate, Sage Rebuffs Biogen, Obesity Space Expands, More
|
Jan 29, 2025 |
|
Trump Takes Over, Wegovy Still Trails Zepbound and BioSpace Recaps JPM
|
Jan 22, 2025 |
|
Bonus: Q4 2024 Job Market Update
|
Jan 21, 2025 |
|
A Conversation with Peter Marks: Insights into GenScript Biotech Forum 2025
|
Jan 16, 2025 |
|
Dispatches From JPM, Biogen’s Sage Buyout Offer, Pfizer’s Obesity Play, More
|
Jan 15, 2025 |
|
A Conversation with Peter Marks and Tom Whitehead: Insights into GenScript Biotech Forum 2025 (Teaser)
|
Jan 10, 2025 |
|
NextGen Class of 2025, M&A Uptick Predicted Heading Into JPM, FDA Decisions to Watch
|
Jan 08, 2025 |
|
Trials and Capital: Women’s Health and APAC's Healthcare Revolution
|
Jan 02, 2025 |
|
Analysis vs Beliefs, CEO Challenges, GLP-1 Investments
|
Dec 19, 2024 |
|
Biopharma’s Manufacturing Push and Other 2024 Trends
|
Dec 18, 2024 |
|
Highlights From ASH, Lilly and Novo’s Manufacturing Boon, Momentum in Neuro, More
|
Dec 11, 2024 |
|
Previous Investment Patterns Set to Repeat in 2025
|
Dec 05, 2024 |
|
Biopharma’s Shopping Spree, Applied Crashes on Rejection, Skysona’s Safety Concerns, More
|
Dec 04, 2024 |
|
BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More
|
Nov 27, 2024 |
|
51%: The Untapped Market
|
Nov 21, 2024 |
|
RFK Jr.’s HHS Nomination, Biogen’s Lupus Win and Leqembi Struggles, Neurogene’s Rough Month, More
|
Nov 20, 2024 |
|
AbbVie’s Surprise Schizophrenia Flop, AstraZeneca’s China Drama, Hope in Huntington’s, More
|
Nov 13, 2024 |
|
Investing in AI: Benefits, Regulatory Challenges
|
Nov 07, 2024 |
|
Lilly’s Q3 Miss, Novo’s MASH Win, CAR T’s Autoimmune Pivot, More
|
Nov 06, 2024 |
|
Pfizer’s Q3 Earnings Win, Deals Galore, Countdown to Election, More
|
Oct 30, 2024 |
|
Steady But Slow: Future Outlook for Investment
|
Oct 24, 2024 |
|
Trodelvy’s Bladder Cancer Withdrawal, Sage Therapeutics Layoffs, Sanofi’s Radiopharma Investment, More
|
Oct 23, 2024 |
|
Q3 Earnings Kick Off With J&J, Bluebird in Tough Spot, Novo-Catalent Deal Under Fire, More
|
Oct 16, 2024 |
|
How AI Could Ease Tension in Clinical Trials
|
Oct 10, 2024 |
|
BioSpace at Meeting on the Mesa, WuXi Considers Selling U.S. Facilities, Big Pharma Layoffs, More
|
Oct 09, 2024 |
|
BMS’ Schizophrenia Approval, Pfizer’s Sudden Sickle Cell Withdrawal and Roche’s Pharma Day
|
Oct 02, 2024 |
|
AI Return on Investment: Just Because We Can, Should We?
|
Sep 26, 2024 |
|
Novo Grilled By Senate, PhRMA’s IRA Win and BMS’ KarXT Awaits Approval
|
Sep 25, 2024 |
|
Sickle Cell Gene Therapies Reach Patients, Moderna Cuts, Obesity Pill Race and ESMO 2024
|
Sep 18, 2024 |
|
AI Promises: Funding Data Literacy and Reality First
|
Sep 12, 2024 |
|
BioMarin Fails to Reassure Investors, Terns Moves Forward in Obesity, ESMO Excitement
|
Sep 11, 2024 |
|
Lilly’s DTC Obesity Push, Layoffs, and an Eye on Ocular Diseases
|
Sep 04, 2024 |
|
Future-Proofing: Inclusive and Protective Patient Strategies
|
Aug 29, 2024 |
|
A Tough Ending, New Beginnings and China-U.S. Biopharma Relations
|
Aug 28, 2024 |
|
New IRA Drug Prices, Lots of Layoffs, Moderna’s Vaccine Opportunity
|
Aug 21, 2024 |
|
Eyes Wide Open: Gaining Patient Trust in the Face of Evolving Women’s Health Policies in State Legislations
|
Aug 15, 2024 |
|
Lykos Rejection, Pfizer’s RSV Win, Lilly Vs. Novo and More
|
Aug 14, 2024 |
|
Pharma Campaign Contributions, Vaccine Hiccups and Lykos’ Moment of Truth
|
Aug 07, 2024 |
|
The Political Shape of the Future Clinical Trial Space
|
Aug 01, 2024 |
|
2 Earnings Bonanza, M&A Accelerates and Alzheimer’s Data
|
Jul 31, 2024 |
|
Layoffs Persist, GLP-1s Launch for Weight Loss in China
|
Jul 24, 2024 |
|
Who Is Driving The Bus - Drug Developers & Healthcare Providers or AI?
|
Jul 18, 2024 |
|
Pfizer’s Oral GLP-1 Push, Lilly Vs. Novo and PBMs Under Pressure
|
Jul 17, 2024 |
|
Lilly’s I&I Play, ADC Investment and GLP-1 Momentum Persists
|
Jul 10, 2024 |
|
FDA Approves Lilly’s Donanemab While Rejections Highlight Manufacturing Issues
|
Jul 03, 2024 |
|
DE&I: Understanding That We Don’t Understand at Molecular Level
|
Jul 02, 2024 |
|
Sarepta’s Big DMD Approval, Alnylam’s Clinical Win and ADA Highlights
|
Jun 26, 2024 |
|
BioSpace at #DIA2024: Workforce Trends, Trial Design, Peter Marks & Recap
|
Jun 20, 2024 |
|
Challenging Research Models to Improve Health Equity
|
Jun 20, 2024 |
|
BIOSECURE’s Surprise Absence, the $100+ Billion Future Weight-Loss Market, DIA and More
|
Jun 19, 2024 |
|
BioSpace at #DIA2024: Convergence and Collaboration
|
Jun 17, 2024 |
|
Donanemab’s Promise, BIO Wrap and Mass Layoffs
|
Jun 12, 2024 |
|
BioSpace x DIA: Robust Integrated Regulatory Strategies
|
Jun 06, 2024 |
|
The ABCs of Biopharma This Week: ASCO, BIO and Cancer
|
Jun 05, 2024 |
|
BioSpace x DIA: Advanced Therapy Product Regulatory Confusion
|
May 30, 2024 |
|
AstraZeneca’s Ambitious Target, Pharma Layoffs Continue and ASCO
|
May 28, 2024 |
|
BioSpace x DIA: Navigating the Emergence of CGT Combination Products
|
May 23, 2024 |
|
Bayer’s New Strategy, Novo Vs. Lilly and Psychedelics
|
May 22, 2024 |
|
Bayer Layoffs, a Big Alzheimer’s Deal and ASGCT Wrap
|
May 15, 2024 |
|
Women's Health: Where Politics and Science Meet
|
May 09, 2024 |
|
ASGCT, Adcomm for Lilly’s Donanemab, Vertex Vs. Bluebird
|
May 08, 2024 |
|
BioSpace Heads to #ASGCT, Along with Thousands in Cell and Gene Therapy
|
May 03, 2024 |
|
The IRA, BMS’ Big Cuts, First WHIM Approval
|
May 01, 2024 |
|
Where Do We Go From Here? The Future of Women's Health
|
Apr 25, 2024 |
|
Sanofi Layoffs, CAR-T Warnings and a New GLP-1 Player
|
Apr 24, 2024 |
|
Amylyx and ALS, Continued ADC Excitement, Dire Drug Shortages
|
Apr 17, 2024 |
|
It's a Design Problem: Women and Clinical Trials
|
Apr 11, 2024 |
|
Alphabet Soup: AACR and ACC Dominate Headlines This Week
|
Apr 10, 2024 |
|
Did WuXi Make a Whoopsie? US-China R&D Relations in Limbo
|
Apr 03, 2024 |
|
Will the IRA’s Focus on the Pharmaceutical Industry Hurt the World’s Healthcare System Instead of Helping Patients?
|
Mar 28, 2024 |
|
Bayer’s sweeping executive cuts, Wegovy’s expanding reach
|
Mar 27, 2024 |
|
Money talk: Salary trends and raises
|
Mar 21, 2024 |
|
Historic approval for MASH, CAR-Ts in the spotlight
|
Mar 20, 2024 |
|
The unintended consequences of small molecules
|
Mar 14, 2024 |
|
The skinny on weight loss, donanemab and the State of the Union
|
Mar 13, 2024 |
|
The ABCs of ADCs: Why antibody-drug conjugates are so hot right now
|
Mar 06, 2024 |
|
The gap is where the pain is: Drug pricing and patient costs
|
Feb 29, 2024 |
|
Sweet succession: Gonzalez, patent thickets and his triumph over biosimilars
|
Feb 28, 2024 |
|
Iovance wins with Amtagvi and the ADC train chugs on
|
Feb 21, 2024 |
|
Eyes on the prize: Novo buys Catalent
|
Feb 14, 2024 |
|
Balancing act: Patient access and innovation
|
Feb 07, 2024 |
|
Keep calm and CAR-T on?
|
Jan 31, 2024 |
|
What can biopharma expect from the job market?
|
Jan 25, 2024 |
|
Grab an umbrella, it's raining IPOs!
|
Jan 24, 2024 |
|
Optimistic, but for how long? Our big takeaways from #JPM2024
|
Jan 17, 2024 |
|
On the ground at #JPM2024 - Day 3 highlights
|
Jan 10, 2024 |
|
On the ground at #JPM2024 - Day 2 highlights
|
Jan 10, 2024 |
|
On the ground at #JPM2024 - Day 1 highlights
|
Jan 08, 2024 |
|
Alternative funding strategies to discuss at JPM with Halia Therapeutics, the ADDF and Triumvira Immunologics
|
Jan 04, 2024 |
|
The top life sciences startups to watch this year
|
Jan 03, 2024 |
|
What VCs look for when investing with MPM Capital, Endeavor Venture Fund and Two Bear Capital
|
Dec 21, 2023 |
|
Every move you make: Biopharma industry under heavy scrutiny
|
Dec 20, 2023 |
|
What VCs really think of the market right now with MPM Capital, Endeavor Venture Fund and Two Bear Capital
|
Dec 14, 2023 |
|
Major FDA approvals for Vertex/CRISPR; bluebird gets black box warning and price scrutiny
|
Dec 13, 2023 |
|
Fast and furious evolution: How to ensure AI is catalyst for positive societal change with Microsoft and IQVIA
|
Dec 12, 2023 |
|
Integrating AI in life sciences to change employee behavior with Microsoft and IQVIA
|
Dec 07, 2023 |
|
GLP-1 and ADC rollercoasters pick up speed
|
Dec 06, 2023 |
|
Artificial Intelligence, Part 3: Improving Communication to Impact Patient Behavior
|
Dec 05, 2023 |
|
Artificial Intelligence, Part 2: Human Interaction, Liability, and Patient Safety
|
Nov 30, 2023 |
|
Deals, Dupixent and GLP-1 drug shortages
|
Nov 29, 2023 |
|
First ever CRISPR gene therapy approval: What happens next?
|
Nov 21, 2023 |
|
Artificial Intelligence, Part 1: Bias, Access, ROI, Potential Success and Failure
|
Nov 16, 2023 |
|
Zepbound vs Wegovy: A two horse race
|
Nov 15, 2023 |
|
Q3 earnings recap: Winners, losers & surprises
|
Nov 08, 2023 |